RedHill Biopharma: RHB-204 receives FDA Fast Track designation for treatment of NTM disease

Retrieved on: 2021-01-07 00:55:47

Tags for this article:

Click the tags to see associated articles and topics

RedHill Biopharma: RHB-204 receives FDA Fast Track designation for treatment of NTM disease. View article details on hiswai:

Excerpt

RedHill Biopharma Ltd. ("RedHill" or "the Company"), a specialty biopharmaceutical company, today announced that RHB-204 has been granted Fast ...

Article found on: www.news-medical.net